WO2004108056A2 - Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease - Google Patents

Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease Download PDF

Info

Publication number
WO2004108056A2
WO2004108056A2 PCT/BR2004/000089 BR2004000089W WO2004108056A2 WO 2004108056 A2 WO2004108056 A2 WO 2004108056A2 BR 2004000089 W BR2004000089 W BR 2004000089W WO 2004108056 A2 WO2004108056 A2 WO 2004108056A2
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
treatment
packing
kit
presentation
Prior art date
Application number
PCT/BR2004/000089
Other languages
French (fr)
Other versions
WO2004108056A3 (en
Inventor
Alexandre FUNARI NEGRÃO
Original Assignee
Medley S.A. Indústria Farmacêutica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medley S.A. Indústria Farmacêutica filed Critical Medley S.A. Indústria Farmacêutica
Publication of WO2004108056A2 publication Critical patent/WO2004108056A2/en
Publication of WO2004108056A3 publication Critical patent/WO2004108056A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Abstract

The present Utility Model is about packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under treatment, characterized by containing in each cartridge, cartouche, blister or similar, one or more ant-platelets, anti-inflammation agents or presenting positive fibernolythic activity, together with one or more agents capable to improve the lipidic blood profile, and optionally one or more medicaments known by the man of technique for this type of treatment, presented in a didactic, clear and safe manner, orienting and informing the patient regarding nature or type of the active principle, dosage, quantity of units of the medicaments, hour of the day to be taken, as well as period of treatment and other information or else according to figures 1 and 2.

Description

PACKING, OR KIT OF MEDICAMENTS, OR FACILITATING PRESENTATION OF ADMINISTERING OF MEDICAMENTS ON THE PART OF INDIVIDUALS UNDER PRENENTIVE SITUATION AND/OR TREATMENT OF THE ATHEROSCLEROSIS DISEASE. The present Utility Model deals about packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under treatment and/or primary and secondary prevention of clinical conditions associated with the ath erosclerosis disease such as: dislipidemia, soft diabetes, obesity, coronary disease, myocardial infarction, cerebric- vascular disease, arterial hypertension, among others.
One of the methods of treatment or prevention of the atherosclerosis disease consists in using medicaments with anti-thrombosis or anti-platelets action, together with a medicament, able to improve the lipidic blood profile, including the total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride.
With the objective to:
• develop in one single facilitating packing, two types of medicaments with
complemental actions, to be administered by the patient during treatment;
• furnish orientation, written in a clear, didactic, safe manner and easy to handle;
• cheapen the final treatment costs for the patient;
• emphasize the importance of the combined use of the medicaments;
• increase the therapeutical adhesion of the patients;
• underscore the importance of the preventive treatment; the solicitant developed a new type of packing, or kit of medicaments, or facilitating presentation of administering medicaments on the part of individuals under treatment, functionality of which has considerably been improved in relation to what can be found on the market.
A type of packing has been developed, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease, characterized by containing in each cartridge, cartouche, blister or similar, one or more anti- thrombosis or anti-platelets agents, together with one or more agents, capable to recover the lipidic blood profile, including the total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, and optionally one or more medicaments known by the man of the technique for this type of treatment, showing written information, printed in a didactic, clear and safe manner, regarding nature or type of the active principle, dosage, quantity of units of the medicaments, hour of the day to be taken, as well as period of treatment and other information.
Anti-thrombosis or anti-platelets or anti-inflammation agents, or presenting fibemolythic positive activity, can be chosen from the group containing: AAS ( salicylic acetylene acid), and ticlopidina employed alone or combined, in different dosages. Preferentially AAS ( salicylic acetylene acid) is being employed, in the dosage of 100 mg, or in higher or lower dosages, according to medical prescription.
Agents capable to improve the lipidic blood profile, that is, pharmaceutics of hypolipemiant or hipocholesterolemic action, can be employed, chosen among the group represented by the estatinas. The estatinas that can be employed are, for example: sinvastatina, atorvastatina, pravastatina, lovastatina, fluvastatina and rosuvastatina in different dosages. Or else can be employed also inhibitors of the intestinal absorption of cholesterol as, for example, ezetimibe, orlistat and cholestiramine, or medicaments with predominant action on the triglycerides as, for example: fribrates - clofibrate, bezafibrate, gemfibrozil, fenofibrate, etofibrate and ciprofibrate - or nicotian acid. Preferentially is being employed sinvastatina in dosages, that may vary between 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, among other possible dosages. The medicamentous agents, according to the utility model, may be presented in form of single unit pills, capsules, tablets, etc.
A preferential form of the utility model is dealing about packing, or kit of medicaments, or medicament administering facilitating presentation on the part of individuals under treatment, characterized by containing in each cartridge, cartouche, blister or similar, one or mote units containing salicylic acetylene acid (AAS), being optionally one or more medicaments known by the man of the technique for the same purpose, offering the patient in a didactic, clear an safe manner, written orientation regarding nature or type of the active principle, dosage, quantity of units of the medicaments, hour of the day to be taken, as well as period of treatment and other information.
In an even more preferential way, the packing, or kit of medicaments, or medicaments administering facilitating presentation on the part of individuals under teatment are being characterized by containing 30 pills of AAS in the unitary dosage of 100 mg and 30 pills of sinvastatina in unitary dosage of 10 mg, or 20 mg, showing indications on the units of medicaments taken per day. Its preferable to administer one unit of sinvastatina daily in the dosage of 10 mg, or 20 mg and one unit of AAS (salicylic acetylene acid ) in the dosage of 100 mg, during a treatment period of 30 days, or else according to Figures 1 and 2.
The aim of the example that follows is to better elucidate the utility model, that should not be taken as basis for restrictive effects of the scope of the utility model.
EXAMPLE 1:
FIGURES 1 and 2 annexed elucidate one of the cartridges contained in the packing according to the utility model, presenting: - The two faces of the cartridge: front ( 1 ) - Figure 1 and rear ( 2 ) - Figure 2;
- The front face ( 1 ) - Figure 1, shows indications on:
. place for commercial name of the product (4): Prevencor 10 or Prevencor 20
(according to dose with reference to sinvastatina 10 mg or 20 mg);
. names of the active principles (3) corresponding to the medicamentous units: sinvastatina and salicylic acetylene acid;
. indications on the pills to be taken per day, or for each day of the treatment (5), that means that the patient should take per treatment day: one pill of salicylic acetylene acid 100 mg (6) and one pill of sinvastatina (7) which, in this case, is being employed in the dosage of 10 mg; . there are quantities of medicaments for 5 days of treatment (5), per cartridge;
- On the rear side of the cartridge (2) - Figure 2, are indications on:
. commercial name of product (4): Prevencor 10 or Prevencor 20 (according to the dose with reference to sinvastatina 10 mg or 20 mg); . names of the active principles (3) that compose the medicaments: sinvastatina (7) 10 mg and salicylic acetylene acid (6) 100 mg.
. indication on each pill contained in the cartridge: salicylic acetylene acid lOOmg (6) and sinvastatina pills lOmg (7).
Figures 1 and 2 represent a cartridge containing medicamentous units, as being indicated in the below table:
Figure imgf000006_0001

Claims

1. Packing or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease, characterized by containing in each cartridge, cartouche, blister or similar, one or more anti-thrombosis or anti-platelets agents, together with one or more agents, capable to recover the lipidic blood profile, including the total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, and optionally one or more medicaments known by the man of the technique for this type of treatment, showing written information, printed in a didactic, clear and safe manner, regarding nature or type of the active principle, dosage, quantity of units of the medicaments, hour of the day to be taken, as well as period of treatment and other information.
2. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 1, characterized by being able to employ anti-thrombosis, anti-platelets or anti-inflammation agents, or presenting fibemolythic positive activity, the ones chosen from the group that comprises: AAS (salicylic acetylene acid), and ticlopidina employed alone or combined in different dosages.
3. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 2, characterized by employing AAS (salicylic acetylene acid ), in the dosage of 100 mg or in higher or lower dosages.
4. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 1, characterized by employing as agents presenting lipolipemiant or hipocholesterolemic actions, substances of the family of the estatinas.
5. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 4, characterized by employing: sinvastatina, atorvastatina, pravastatina, lovastatina, fluvastatina and rosuvastatina in different dosages.
6. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claims 1 or 5, characterized by preferentially employing sinvastatina in dosages that may vary between 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, among other dosages.
7. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 1, characterized by being able to employ inhibitors of intestinal absorption of cholesterol as, for example, ezetimibe, orlistat and cholestiramina.
8. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 1 , characterized by being able to employ medicaments with a predominant action on the triglycerides as, for example,: fribrates - clofibrate, bezafibrate, gemfibrozil, fenofibrate, etofibrate and ciprofibrate - or nicotian acid.
9. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease according to claim 1, characterized by the fact that the medicamentous units present themselves in the form of pills, capsules, tablets, etc.
10. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease, characterized by containing each cartridge, cartouche, blister or similar, units with salicylic acetylene acid (AAS), and units of one or more estatinas, optionally one or more medicaments known by the man of the technique for this type of treatment, showing written information, printed in a didactic, clear and safe manner, regarding nature or type of the active principle, dosage, quantity of units of the medicaments, hour of the day to be taken, as well as period of treatment and other information.
11. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease, characterized by containig 30 pills of AAS in the unitaiy dosage of 100 mg and 30 pills of sinvastatina in unitary dosage of 10 mg, or 20 mg,
\ showing indications on the medicamentous units taken during the day.
12. Packing, or kit of medicaments, or facilitating administering presentation of medicaments on the part of individuals under prevention and/or treatment of the atherosclerosis disease, characterized by containing sufficient medicamentous units for administering one unit per day of sinvastatina in the dosage of 10 mg, or 20 mg and one unit of AAS (salicylic acetylene acid ) in the dosage of 100 mg, during a treatment period of 30 days, or even according to FIGURES 1 and 2.
PCT/BR2004/000089 2003-06-10 2004-06-09 Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease WO2004108056A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR8302502U BR8302502U (en) 2003-06-10 2003-06-10 Packaging, or drug kit, or facilitative presentation of drug administration by individuals in prevention and / or treatment of atherosclerotic disease
BRMU8302502-2 2003-06-10

Publications (2)

Publication Number Publication Date
WO2004108056A2 true WO2004108056A2 (en) 2004-12-16
WO2004108056A3 WO2004108056A3 (en) 2008-01-10

Family

ID=38895611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000089 WO2004108056A2 (en) 2003-06-10 2004-06-09 Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease

Country Status (2)

Country Link
BR (1) BR8302502U (en)
WO (1) WO2004108056A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047123A1 (en) * 1998-03-18 1999-09-23 Bristol-Myers Squibb Company Pharmaceutical composition containing a statin and aspirin
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US20030013688A1 (en) * 2001-06-21 2003-01-16 Rene Belder Synergistic combination of pravastatin and aspirin and method
US20030049314A1 (en) * 2001-08-28 2003-03-13 Liang Matthew H. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047123A1 (en) * 1998-03-18 1999-09-23 Bristol-Myers Squibb Company Pharmaceutical composition containing a statin and aspirin
US20020034546A1 (en) * 1998-03-18 2002-03-21 Ismat Ullah Pharmaceutical composition containing a combination of a statin and aspirin and method
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US20030013688A1 (en) * 2001-06-21 2003-01-16 Rene Belder Synergistic combination of pravastatin and aspirin and method
US20030049314A1 (en) * 2001-08-28 2003-03-13 Liang Matthew H. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEIN E A: "UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET?" ADVANCED STUDIES IN MEDICINE, vol. 3, no. 4C, April 2003 (2003-04), pages S306-S310, XP008027522 *

Also Published As

Publication number Publication date
WO2004108056A3 (en) 2008-01-10
BR8302502U (en) 2005-04-19

Similar Documents

Publication Publication Date Title
Heck et al. Orlistat, a new lipase inhibitor for the management of obesity
US6121249A (en) Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
Winokur et al. Withdrawal reaction from long-term, low-dosage administration of diazepam: A double-blind, placebo-controlled case study
TWI305726B (en) Medicaments for diabetic complication and neuropathy
KR20150016405A (en) Methods of treating overweight and obesity
McKay Long-term use of diethylpropion in obesity
AU758181B2 (en) Therapeutic agents
NL8320239A (en) IMPROVED ANALGETIC AND ANTI-INFLAMMATORY PREPARATIONS INCLUDING IBUPROPHES AND METHOD FOR USE THEREOF.
US20080181937A1 (en) Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
Zhu et al. Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
WO2004108056A2 (en) Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease
MAY et al. Parkinsonian reactions following chlorpromazine and reserpine: Similar reactions in the same patients
JP2022133449A (en) Levodopa division dose composition and use
Wright et al. Indomethacin in the treatment of rheumatoid arthritis. A controlled trial comparing indomethacin, phenylbutazone, and placebo.
Sandyk Anticholinergic-induced analgesia: possible role for the cholinergic system in abnormal sensory symptoms in Parkinson's disease
US20070053930A1 (en) Combination therapy for treatment of high cholesterol
Abbas Use of thioridazine in palliative care patients with troublesome sweating
RU52331U1 (en) CARDIOLOGICAL FIRST-AID KIT FOR PROVISION OF EMERGENCY SELF-AND MUTUAL AID "TRICARD"
McNulty et al. Pediatric nifedipine overdose with survival after cardiac arrest
Murphy Treatment of Parkinsonism with laevodopa
Henwood et al. Medicines: The Good, The Not So Good, and The Sometimes Overused
Martens Double-blind randomized comparison of proglumetacin and naproxen sodium in the treatment of patients with ankle sprains
Rhind et al. A comparative study of floctafenine (Idarac) and ibuprofen in the treatment of osteoarthrosis
Ressler et al. Clinical evaluation of phendimetrazine bitartrate
RU2149013C1 (en) Method and biostimulation means for treating somatic diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase